RxDoctor Payments Data

Allie Hutchison, PA

Medical · Cambridge, MDNPI 1093478323

Payments from drug & device makers

$1,112in general payments, 2019–2025

Across 54 payments — averaging $20.60 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Lilly USA, LLC$305
  • Astellas Pharma US Inc$194
  • Amgen$92
  • Pfizer$78
  • Novo Nordisk$68
  • Sanofi Pasteur Inc.$64
  • plus $313 from 10 others

What the payments were for

  • Food & beverage$1,112100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,112 in reported general payments places this provider in the 65th percentile of 543 medical providers in Maryland.

See all medical providers in Maryland

Medicare billing

Part B allowed, 2024
$97,185
Medicare patients
589
Services billed
1,304

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide28$41,154
EliquisApixaban37$34,779
JanuviaSitagliptin Phosphate22$19,697
JardianceEmpagliflozin21$17,633
EntrestoSacubitril/Valsartan14$10,364
Atorvastatin Calcium211$3,007
Losartan Potassium93$1,716
Metoprolol Succinate101$1,688
Amlodipine Besylate145$1,462
Rosuvastatin Calcium47$1,291
Levothyroxine Sodium142$1,279
Gabapentin99$1,266
Duloxetine Hcl32$1,010
Albuterol Sulfate HfaAlbuterol Sulfate39$927
Potassium Chloride36$850

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$68$41,15428 claims
PfizerEliquis$78$34,77937 claims
NovartisEntresto$16$10,36414 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 543 medical providers in Maryland.

Other medical in Cambridge

See the full list for Maryland

Where these figures come from

Is this you, or does something look wrong? →